Role of cysteine S-conjugate β-lyase in the metabolism of cisplatin

Journal of Pharmacology and Experimental Therapeutics

Volumn 306, Issue 3, 2003, Pages 988-994

  Zhang, Lei ^a   Hanigan, Marie H ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b Biomedical Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYSTEINE S CONJUGATE BETA LYASE; DRUG METABOLITE; LYASE; PLATINUM CYSTEINE S CONJUGATE; THIOL GROUP; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CATALYSIS; CELL DIVISION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG MECHANISM; DRUG METABOLISM; ELIMINATION REACTION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; KIDNEY PROXIMAL TUBULE; MONOLAYER CULTURE; NEPHROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TOXICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARBON-SULFUR LYASES; CARBOPLATIN; CELL LINE; CISPLATIN; HUMANS; KIDNEY; LYASES; SWINE; TRANSAMINASES; TRANSFECTION;

EID: 0042433316     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.052225     Document Type: Article

References (36)

1. Abraham DG and Cooper AJ (1991) Glutamine transaminase K and cysteine Sconjugate β-lyase activity stains. Anal Biochem 197:421-427.
2. Abraham DG and Cooper AJ (1996) Cloning and expression of a rat kidney cytosolic glutamine transaminase K that has strong sequence homology to kynurenine pyruvate aminotransferase. Arch Biochem Biophys 335:311-320.
3. Abraham DG, Patel PP, and Cooper AJ (1995) Isolation from rat kidney of a cytosolic high molecular weight cysteine-S-conjugate β-lyase with activity toward leukotriene E4. J Biol Chem 270:180-188.
4. Adcock HJ, Gaskin PJ, Shaw PN, Teesdale-Spittle PH, and Buckberry LD (1996) Novel sources of mammalian C-S lyase activity. J Pharm Pharmacol 48:150-153.
5. Anders MW and Dekant W (1998) Glutathione-dependent bioactivation of haloalkenes. Annu Rev Pharmacol Toxicol 38:501-537.
6. Birner G, Richling C, Henschler D, Anders MW, and Dekant W (1994) Metabolism of tetrachloroethene in rats: identification of N-ε-(dichloroacetyl)-L-lysine and N-ε-(trichloroacetyl)-L-lysine as protein adducts. Chem Res Toxicol 7:724-732.
7. Cooper AJ (1998) Mechanisms of cysteine S-conjugate β-lyases. Adv Enzymol Relat Areas Mol Biol 72:199-238.
8. Cooper AJ, Bruschi SA, and Anders MW (2002) Toxic, halogenated cysteine Sconjugates and targeting of mitochondrial enzymes of energy metabolism. Biochem Pharmacol 64:553-564.
9. Cooper AJ, Wang J, Gartner CA, and Bruschi SA (2001) Co-purification of mitochondrial HSP70 and mature protein disulfide isomerase with a functional rat kidney high-Mr cysteine S-conjugate beta-lyase. Biochem Pharmacol 62:1345-1353.
10. Cornelison TL and Reed E (1993) Nephrotoxicity and hydration management for cisplatin, carboplatin and ormaplatin. Gynecol Oncol 50:147-158.
11. deCeaurriz J and Ban M (1990) Role of gamma-glutamyl transpeptidase and β-lyase in the nephrotoxicity of hexachloro-1,3-butadiene and methyl mercury in mice. Tox Lett 50:249-256.
12. Dedon PC and Borch RF (1987) Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles. Biochem Pharmacol 36:1955-1964.
13. Elfarra AA, Jakobson I, and Anders MW (1986) Mechanism of S-(1,2-dichlorovinyl)-glutathione-induced nephrotoxicity. Biochem Pharmacol 35:283-288.
14. Fink D and Howell SB (2000) How does cisplatin kill cells, in Platinum-Based Drugs in Cancer Therapy (Kelland LR and Favilli F eds) pp 149-167, Humana Press, Totowa, NJ.
15. Gaskin PJ, Adcock HJ, Buckberry LD, Teesdale-Spittle PH, and Shaw PN (1995) The C-S lysis of L-cysteine conjugates by aspartate and alanine aminotransferase enzymes. Hum Exp Toxicol 14:422-427.
16. Goldfarb P, Perry S, Harries H, Scholfield C, Lock T, King L, and Gibson G (1996) Molecular cloning and expression of cDNAs for rat and human kidney cysteine conjugate β-lyase. Biochem Soc Trans 24:330S.
17. Hanigan MH, Gallagher BC, Taylor PT Jr, and Large MK (1994) Inhibition of gamma-glutamyl transpeptidase activity by acivicin in vivo protects the kidney from cisplatin-induced toxicity. Cancer Res 54:5925-5929.
18. Hanigan MH, Lykissa ED, Townsend DM, Ou C, Barrios R, and Lieberman MW (2001) γ-Glutamyl transpeptidase-deficient mice are resistant to the nephrotoxicity of cisplatin. Am J Pathol 159:1889-1894.
19. Hayden PJ, Ichimura T, McCann DJ, Pohl LR, and Stevens JL (1991) Detection of cysteine conjugate metabolite adduct formation with specific mitochondrial proteins using antibodies raised against halothane metabolite adducts. J Biol Chem 266:18415-18418.
20. Jones TW, Chen Q, Schaeffer VH, and Stevens JL (1988) Immunohistochemical localization of glutamine transaminase K, a rat kidney cysteine conjugate β-lyase and the relationship to the segment specificity of cysteine conjugate nephrotoxicity. Mol Pharmacol 34:621-627.
21. Lash LH, Elfarra AA, Rakiewicz-Nemeth D, and Anders MW (1990) Bioactivation mechanism of cytotoxic homocysteine S-conjugates. Arch Biochem Biophys 276:322-330.
22. Lash LH, Sausen PJ, Duescher RJ, Cooley AJ, and Elfarra AA (1994) Roles of cysteine conjugate β-lyase and S-oxidase in nephrotoxicity: studies with S-(1,2-dichlorovinyl)-L-cysteine and S-(1,2-dichlorovinyl)-L-cysteine sulfoxide. J Pharmacol Exp Ther 269:374-383.
23. McKeage MJ (2000) Clinical toxicology of platinum-based cancer chemotherapeutic agents, in Platinum-Based Drugs in Cancer Therapy (Kelland LR and Farrell NP eds) pp 251-275, Humana Press, Totowa, NJ.
24. McKinney LL, Picken JC Jr, Weakley FB, Eldridge AC, Campbell RE, Cowan JC, and Biester HE (1959) Possible toxic factor of trichloroethylene-extracted soybean oil meal. J Am Chem Soc 81:909-915.
25. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
26. O'Dwyer PJ, Stevenson JP, and Johnson SW (1999) Clinical Status of Cisplatin, Carboplatin and Other Platinum-Based Antitumor Drugs, in Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug (Lippert B ed) pp 29-70, Wiley-VCH, Zurich.
27. Perez RP (1998) Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 34:1535-1542.
28. Perry S, Harries H, Scholfield C, Lock T, King L, Gibson G, and Goldfarb P (1995) Molecular cloning and expression of a cDNA for human kidney cysteine conjugate β-lyase. FEBS Lett 360:277-280.
29. Perry SJ, Schofield MA, MacFarlane M, Lock EA, King LJ, Gibson GG, and Goldfarb PS (1993) Isolation and expression of a cDNA coding for rat kidney cytosolic cysteine conjugate β-lyase. Mol Pharmacol 43:660-665.
30. Sadowitz PD, Hubbard BA, Dabrowiak JC, Goodisman J, Tacka KA, Aktas MK, Cunningham MJ, Dubowy RL, and Souid AK (2002) Kinetics of cisplatin binding to cellular DNA and modulations by thiol-blocking agents and thiol drugs. Drug Metab Dispos 30:183-190.
31. Stevens JL (1985) Isolation and characterization of a rat liver enzyme with both cysteine conjugate β-lyase and kynureninase activity. J Biol Chem 260:7945-7950.
32. Stevens JL, Robbins JD, and Byrd RA (1986) A purified cysteine conjugate α-lyase from rat kidney cytosol. Requirement for an α-keto acid or an amino acid oxidase for activity and identity with soluble glutamine transaminase K. J Biol Chem 261:15529-15537.
33. Townsend DM, Deng M, Zhang L, Lapus MG, and Hanigan MH (2003a) Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 14:1-10.
34. Townsend DM and Hanigan MH (2002) Inhibition of γ-glutamyl transpeptidase or cysteine S-conjugate β-lyase activity blocks the nephrotoxicity of cisplatin in mice. J Pharmacol Exp Ther 300:142-148.
35. Townsend DM, Marto JA, Deng M, Macdonald TJ, and Hanigan MH (2003b) High pressure liquid chromatography and mass spectrometry characterization of the nephrotoxic biotransformation products of cisplatin. Drug Metab Dispos 31:705-713.
36. Trevisan A, Cristofori P, Fanelli G, Bicciato F, and Stocco E (1998) Glutamine transaminase K intranephron localization in rats determined by urinary excretion after treatment with segment-specific nephrotoxicants. Arch Toxicol 72:531-535.